Literature DB >> 11055821

Haematogenous vertebral osteomyelitis in the elderly.

J Belzunegui1, J J Intxausti, J R De Dios, N Del Val, V Rodríguez Valverde, C González, R Queiro, M Figueroa.   

Abstract

The aim of our study was to analyse the characteristics of haematogenous vertebral osteomyelitis (HVO) in the elderly. A retrospective comparative analysis of the medical records of 72 patients (38 younger than 63 years, group 1, and 34 aged 63 years and over, group 2) with haematogenous vertebral osteomyelitis of confirmed aetiology was carried out. Intravenous drug addiction and infection with the human immunodeficiency virus were seen in 4/38 (10%) and 5/38 (13%) patients from group 1 and 0/34 patients (0%) from group 2 (P = 0.05 and 0.035, respectively). Seven of 34 elderly (20%) and 0/38 (0%) young individuals had recently had surgery (P = 0.0036). Escherichia coli was isolated in 7/34 elderly (20%) and 0/38 (0%) young patients (P = 0.0036). The remaining studied data did not reach statistical significance. Recent surgery is a risk factor for developing HVO in the elderly, the urinary tract being the source of the pathogen in a large number of elderly patients with spinal infection.

Entities:  

Mesh:

Year:  2000        PMID: 11055821     DOI: 10.1007/pl00011175

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  12 in total

1.  Group A streptococcal vertebral osteomyelitis presenting with acute quadriplegia.

Authors:  M Furitsch; K Träger; M van der Linden; B Spellerberg
Journal:  Infection       Date:  2011-04-22       Impact factor: 3.553

2.  Clinical findings of vertebral osteomyelitis: Brucella spp. versus other etiologic agents.

Authors:  Elif Sahin Horasan; Mehmet Colak; Gülden Ersöz; Mustafa Uğuz; Ali Kaya
Journal:  Rheumatol Int       Date:  2011-11-06       Impact factor: 2.631

3.  Conservative management of spinal tuberculosis: initial series from pakistan.

Authors:  Asad Abbas; Syed Raza Haider Rizvi; Mufaddal Mahesri; Hisham Raza Aleem Salahuddin
Journal:  Asian Spine J       Date:  2013-05-22

Review 4.  Surgical treatment of pyogenic vertebral osteomyelitis with spinal instrumentation.

Authors:  Wei-Hua Chen; Lei-Sheng Jiang; Li-Yang Dai
Journal:  Eur Spine J       Date:  2006-11-15       Impact factor: 3.134

5.  A novel canine model of acute pyogenic spondylodiscitis.

Authors:  Wei-Hua Chen; Lei-Sheng Jiang; Li-Yang Dai
Journal:  Neurosurg Rev       Date:  2009-07-15       Impact factor: 3.042

6.  The epidemiology of hematogenous vertebral osteomyelitis: a cohort study in a tertiary care hospital.

Authors:  Kavita P Bhavan; Jonas Marschall; Margaret A Olsen; Victoria J Fraser; Neill M Wright; David K Warren
Journal:  BMC Infect Dis       Date:  2010-06-07       Impact factor: 3.090

7.  Pyogenic vertebral osteomyelitis: identification of microorganism and laboratory markers used to predict clinical outcome.

Authors:  Sang Hoon Yoon; Sang Ki Chung; Ki-Jeong Kim; Hyun-Jib Kim; Yong Jun Jin; Hong Bin Kim
Journal:  Eur Spine J       Date:  2009-11-24       Impact factor: 3.134

8.  Spondylodiscitis Due to Aspergillus terreus in an Immunocompetent Host: Case Report and Literature Review.

Authors:  Pauline Comacle; Yohann Le Govic; Cyril Hoche-Delchet; Jeremy Sandrini; Claire Aguilar; Benjamin Bouyer; Sophie Blanchi; Pascale Penn
Journal:  Mycopathologia       Date:  2016-04-02       Impact factor: 2.574

9.  Clinical characteristics and risk factors of pyogenic spondylitis caused by gram-negative bacteria.

Authors:  Seung-Ji Kang; Hee-Chang Jang; Sook-In Jung; Pyoeng Gyun Choe; Wan Beom Park; Chung-Jong Kim; Kyoung-Ho Song; Eu Suk Kim; Hong Bin Kim; Myoung-Don Oh; Nam Joong Kim; Kyung-Hwa Park
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

10.  Pyogenic vertebral osteomyelitis of the elderly: Characteristics and outcomes.

Authors:  Johan Courjon; Adrien Lemaignen; Idir Ghout; Audrey Therby; Nadia Belmatoug; Aurélien Dinh; Guillaume Gras; Louis Bernard
Journal:  PLoS One       Date:  2017-12-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.